Skip to main content

EDITORIAL article

Front. Med.
Sec. Rheumatology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1491035
This article is part of the Research Topic Autoantibodies for Diagnostics, Prognostics, and Surveillance in Autoimmune Disease View all 12 articles

Editorial: Autoantibodies for Diagnostics, Prognostics, and Surveillance in Autoimmune Disease

Provisionally accepted
Helena Enocsson Helena Enocsson 1*Ingrid Lundberg Ingrid Lundberg 2Martin Herrmann Martin Herrmann 3,4Ioannis Parodis Ioannis Parodis 2,5Christopher Sjöwall Christopher Sjöwall 1*
  • 1 Division of Inflammation and Infection (II), Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Östergötland, Sweden
  • 2 Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet (KI), Solna, Stockholm, Sweden
  • 3 Department of Internal Medicine 3, Rheumatology and Immunology, Faculty of Medicine, University of Erlangen Nuremberg, Erlangen, Bavaria, Germany
  • 4 Deutsches Zentrum Immuntherapie, Medizinische Fakultät, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bavaria, Germany
  • 5 Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

The final, formatted version of the article will be published soon.

    Keywords: Autoantibodies, Autoimmunity, rheumatoid arthritis, autoimmune liver disease (ALD), Myositis, Antiphospholipid sydrome, Antinuclear antibodies (ANA), type I IFN

    Received: 04 Sep 2024; Accepted: 09 Sep 2024.

    Copyright: © 2024 Enocsson, Lundberg, Herrmann, Parodis and Sjöwall. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Helena Enocsson, Division of Inflammation and Infection (II), Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, 581 83, Östergötland, Sweden
    Christopher Sjöwall, Division of Inflammation and Infection (II), Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, 581 83, Östergötland, Sweden

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.